Published in final edited form as:

Biochem Pharmacol. 2007 October 15; 74(8): 1235–1246. doi:10.1016/j.bcp.2007.07.032.

The Subtypes of Nicotinic Acetylcholine Receptors on Dopaminergic Terminals of Mouse Striatum

Sharon R Grady¹, Outi Salminen², Duncan C. Lavery¹, Paul Whiteaker¹, J. Michael McIntosh³, Allan C. Collins¹, and Michael J Marks¹

¹Institute for Behavioral Genetics, University of Colorado, Boulder, CO, USA ²University of Helsinki, Helsinki, Finland ³Departments of Biology and Psychiatry, University of Utah, Salt Lake City, Utah, USA

Abstract

This review summarizes studies that attempted to determine the subtypes of nicotinic acetylcholine receptors (nAChR) expressed in the dopaminergic nerve terminals in the mouse. A variety of experimental approaches has been necessary to reach current knowledge of these subtypes, including *in situ* hybridization, agonist and antagonist binding, function measured by neurotransmitter release from synaptosomal preparations, and immunoprecipitation by selective antibodies. Early developments that facilitated this effort include the radioactive labeling of selective binding agents, such as [¹²⁵I]- α -bungarotoxin and [³H]-nicotine, advances in cloning the subunits, and expression and evaluation of function of combinations of subunits in *Xenopus* oocytes. The discovery of epibatidine and α -conotoxin MII (α -CtxMII), and the development of nAChR subunit null mutant mice have been invaluable in determining which nAChR subunits are important for expression and function in mice, as well as allowing validation of the specificity of subunit specific antibodies. These approaches have identified five nAChR subtypes of nAChR that are expressed on dopaminergic nerve terminals. Three of these contain the $\alpha 6$ subunit ($\alpha 4\alpha 6\beta 2\beta 3$, $\alpha 6\beta 2\beta 3$, $\alpha 6\beta 2$) and bind α -CtxMII with high affinity. One of these three subtypes ($\alpha 4\alpha 6\beta 2\beta 3$) also has the highest sensitivity to nicotine of any native nAChR that has been studied, to date. The two subtypes that do not have high affinity for α -CtxMII ($\alpha 4\beta 2$, $\alpha 4\alpha 5\beta 2$) are somewhat more numerous than the $\alpha 6^*$ subtypes, but do bind nicotine with high affinity. Given that our first studies detected readily measured differences in sensitivity to agonists and antagonists among these five nAChR subtypes, it seems likely that subtype selective compounds could be developed that would allow therapeutic manipulation of diverse nAChRs that have been implicated in a number of human conditions.

Alterations in nicotinic cholinergic receptor (nAChRs) number or function have been implicated in psychopathologies such as anxiety, attention deficit hyperactivity disorder, depression, schizophrenia (reviewed in [1,2,3]), at least one form of familial epilepsy [4], and Parkinson's and Alzheimer's diseases [5]. It is not particularly surprising that nAChRs might play important roles in modulating several human diseases given that binding sites for nicotinic ligands such as [¹²⁵I]- α -bungarotoxin [6,7,8], [³H]-nicotine [7,8], and [³H]-epibatidine [9,

© 2007 Elsevier Inc. All rights reserved.

Corresponding author: Sharon R Grady e-mail: sharon.grady@colorado.edu phone: 303-492-9677 fax: 303-492-8063 mailing address: Institute for Behavioral Genetics University of Colorado 447UCB Boulder, CO 80309.

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

10], are expressed throughout the brain and spinal cord. These binding sites are clearly functional since studies done in laboratory animals and model systems have demonstrated that nicotine treatment produces a broad array of behavioral and physiological effects that are blocked by pretreatment with nicotinic antagonists such as mecamylamine. For example, nicotine injection enhances several components of learning and memory in rats and mice [11,12,13], decreases anxiety [14] and pain perception [15,16], and increases or decreases locomotor activity, depending on dose, species and strain [17,18]. Nicotine treatment also protects animals and neuronal cells in culture from cell death produced by several neurotoxic chemicals [19,20,21,22].

The findings that nAChRs are broadly expressed in brain and that nicotine treatments evoke many physiological changes suggest that nicotinic compounds might prove to be useful for treating human disease. Nicotinic agonists, most notably nicotine and varenacline, have proven to be of some use in smoking cessation programs, but nicotinic agonists have not proven to be of much value when given to nonsmokers. Toxic actions (eg. increases in heart rate, blood pressure and gastrointestinal tone [[23,24,25], and seizures at high doses [26,27]) have served to limit the therapeutic usefulness of nicotinic agonists. These unwanted effects might be minimized, or eliminated, if agents with greater selectivity are developed. .

Neuronal nAChRs are pentameric complexes that closely resemble the nAChR found at the neuromuscular junction, [28,29]. Consequently, the presence of nine nAChR subunit genes ($\alpha 2$ - $\alpha 7$, $\beta 2$ - $\beta 4$) in mammalian brain (see [30] for a recent review) suggests that many, perhaps hundreds, of nAChR subtypes might be expressed in brain. Homomeric and heteromeric nAChRs expressed in *Xenopus laevis* oocytes or cell lines have demonstrated that subunit composition markedly affects biophysical properties (channel open time, desensitization rate, ion selectivity) as well as sensitivities to agonists and antagonists [31,32,33,34]. Studying functional properties of the naturally occurring (native) neuronal nAChRs has been important in identifying the subunit compositions and sites of expression of nAChRs. The observation that subunit composition has profound effects on the potencies and efficacies of routinely available nicotinic drugs suggests that new agents might be developed that are highly subtype selective and thereby could be used to treat disease with limited, or reduced, toxic side effects.

Electrophysiological evidence indicates that nAChRs are expressed on dendrites, cell bodies, axons as well as in perisynaptic and presynaptic sites [30]. Those receptors that are expressed on or near nerve terminals modulate calcium-dependent release of neurotransmitters [35,36, 37,38] including dopamine [39,40,41,42], norepinephrine [43,44], glutamate [45,46], GABA [47], and acetylcholine [48,49]. Nicotinic agonist-stimulated release of dopamine has been studied extensively in the nucleus accumbens because these nAChRs may play a major role in regulating the reinforcing effects of nicotine [50,51,52]. In the striatum, modulation of dopamine release by nAChRs may affect symptoms as well as the pathological degeneration of the dopaminergic neurons in Parkinson's disease [53]. Interest in nicotinic regulation of the dopamine system has also been stimulated by the observations that some of nicotine's effects on learning and memory [54,55], anxiety [56,57] and locomotor activation [58,59] may result as a consequence of dopamine release. Additional interest in nAChR-dopamine interactions comes from the observations that individuals suffering from dopamine-related psychopathologies such as schizophrenia and attention deficit hyperactivity are frequently smokers (incidence > 50-60%) [60,61] and that smoking may retard the onset of Parkinson's disease [62].

The development of subtype selective nAChR agonists and antagonists requires that the subunit compositions of native nAChR subtypes be identified. The experiments described here used molecular biological, biochemical and pharmacological approaches in a series of studies that were designed to identify the subunit compositions of the nAChR subtypes that are expressed

in mouse brain dopaminergic nerve terminals. The results obtained indicate that a minimum of five different subtypes are expressed in dopaminergic nerve terminals. The pharmacological evaluations demonstrate that those nAChRs that include $\alpha 6$, $\alpha 4$, $\beta 2$ and $\beta 3$ subunits have the highest sensitivity for nicotine of any native receptors that have been described, to date [63].

In situ hybridization has been used to characterize mRNA expression patterns in brain tissue. Figure 1 presents the results of *in situ* hybridization experiments that determined the mRNA expression patterns of the $\alpha 2$, $\alpha 3$, $\alpha 4$, $\alpha 5$, $\alpha 6$, $\alpha 7$, $\beta 2$, $\beta 3$, and $\beta 4$ subunits in coronal sections of mouse (C57BL/6) brain [64]. The coronal sections shown in Figure 1 include the ventral tegmental area (VTA) and the substantia nigra (SN), brain regions that have high concentrations of dopaminergic neurons. The VTA and SN express high concentrations of $\alpha 4$, $\alpha 6$, $\beta 2$, and $\beta 3$ mRNAs, intermediate levels of $\alpha 5$ mRNA, and low levels of the $\alpha 3$ and $\alpha 7$ mRNAs. No signal for $\alpha 2$ and $\beta 4$ mRNA was detected. Le Novère et al., [65] obtained virtually identical results in a study that measured *in situ* hybridization of the $\alpha 3$, $\alpha 4$, $\alpha 5$, $\alpha 6$, $\beta 2$, $\beta 3$ and $\beta 4$ mRNAs in catecholamine-rich rat brain regions. These findings suggest that more than one nAChR subtype is expressed in dopaminergic neurons, but this conclusion must be treated with caution because the *in situ* hybridization strategies that were used in the studies discussed above lack the anatomical resolution required to determine whether specific cell types express a given mRNA. This is a major problem given that these dopamine-rich brain regions also include high concentrations of GABAergic neurons [30].

The lack of anatomical resolution associated with standard *in situ* hybridization studies prompted two experiments that were designed to assess mRNA expression in dopaminergic cells. One of these used a double-label *in situ* hybridization approach where the mRNAs for tyrosine hydroxylase, the rate limiting enzyme involved in dopamine synthesis, and nAChR mRNAs were measured in rat brain SN and VTA [66]. These studies detected $\alpha 4$, $\alpha 5$, $\alpha 6$, $\beta 2$ and $\beta 3$ mRNAs in nearly every dopaminergic cell body in the VTA and SN. More than half of these neurons also expressed the $\alpha 3$ and $\alpha 7$ mRNAs and less than 10% expressed $\beta 4$ mRNA. The second approach used single-cell reverse transcriptase polymerase chain reaction (RT-PCR) method to determine nAChR subunit gene mRNA expression in rat VTA and SN dopaminergic neurons [67]. This method detected $\alpha 4$ mRNA in virtually every SN and VTA dopaminergic cell body. Inconsistent results were obtained when $\beta 2$ mRNA was measured; one oligonucleotide probe detected $\beta 2$ mRNA in about 50% of the dopaminergic neurons whereas a second probe, deemed by the authors as more reliable, detected $\beta 2$ mRNA in every dopaminergic cell that was studied. The $\alpha 5$, $\alpha 6$ and $\beta 3$ mRNAs were detected in most (>70%) of the dopaminergic neurons, both $\alpha 3$ and $\alpha 7$ mRNAs were found in approximately 50% of dopaminergic neurons, $\beta 4$ mRNA was encountered in approximately 12% of dopamine neurons and $\alpha 2$ mRNA was never detected. Thus, the mRNA measurement studies (*in situ* hybridization and RT-PCR) argue that nearly all dopaminergic neurons express $\alpha 4$, $\alpha 5$, $\alpha 6$, $\beta 2$ and $\beta 3$ subunit mRNAs and that $\alpha 3$ and $\alpha 7$ mRNAs are also expressed, but in fewer dopaminergic cells. Available evidence indicates that $\alpha 2$ and $\beta 4$ mRNAs are rarely, if ever, expressed in dopaminergic neurons. These findings suggest that several, if not many, different nAChR subtypes may be expressed in dopaminergic neurons.

It is absolutely true that protein cannot be made without mRNA, but it is also true that the presence of mRNA does not guarantee that the protein product is formed or, if it is, how much is formed. Consequently, techniques that measure nAChR proteins must be employed to determine whether the mRNA is translated into a protein that is actually incorporated into a nAChR. Ligand binding assays have been used for over 40 years to detect and quantify the nAChR subunit proteins that are expressed in brain tissue. The first ligands that were developed, [125 I]- α -bungarotoxin [68] and [3 H]-nicotine [69], provided the first reliable evidence that mammalian brain might express nAChRs that resemble those that are found in the periphery. Early observations that the biochemical properties and anatomical distributions

of [125 I]- α -bungarotoxin and [3 H]-nicotine binding differed from one another in both mouse [6] and rat [7] brain suggested that more than one class of nAChRs may be expressed in brain; i.e. nAChR subtypes exist. Almost all of the reports that described the cloning and sequencing of the eleven known nAChR subunit genes included studies that compared *in situ* hybridization and autoradiographic measurement of [125 I]- α -bungarotoxin and [3 H]-nicotine binding. These comparisons suggested that $\alpha 7$ subunits most likely play critical roles in forming the [125 I]- α -bungarotoxin site and that both $\alpha 4$ and $\beta 2$ subunits make up the high affinity [3 H]-nicotine binding site. These conclusions were conclusively confirmed by the finding that deleting the $\alpha 7$ subunit resulted in elimination of the [125 I]- α -bungarotoxin binding site [70] and that null mutation of either the $\alpha 4$ [71] or $\beta 2$ [72] subunit genes resulted in loss of the high affinity [3 H]-nicotine binding site.

Ongoing research is attempting to identify and characterize new ligands that might be useful in measuring brain nAChRs that are not measured with [125 I]- α -bungarotoxin or [3 H]-agonists. Early attempts to develop new ligands demonstrated that agonists such as [3 H]-cytisine [73] and [3 H]-ACh [74] could be used to measure rat and mouse brain nAChRs. However, it quickly became apparent that [3 H]-cytisine and [3 H]-ACh bind to the same receptors ($\alpha 4\beta 2^*$) that bind [3 H]-nicotine with high affinity [73,75,76,77,78,79] demonstrating that what is routinely referred to as high affinity nicotine binding sites should be referred to as high affinity agonist binding sites. A little more than 10 years ago, two new high affinity ligands were introduced to the field, radiolabeled epibatidine [80,81] and α -conotoxin MII (α -CtxMII) [82,83]. [3 H]-Epibatidine was originally described as being a very high affinity ligand that was useful, principally, for measuring $\alpha 4\beta 2^*$ nAChRs [80,81] (* indicates possible additional subunits). However, [3 H]-epibatidine binding exceeded that of [3 H]-cytisine in several regions, and was present in some brain regions (optic nerve, optic chiasm, optic tract) that had no detectable [3 H]-agonist binding sites [9] suggesting that epibatidine labels sites in addition to $\alpha 4\beta 2$ -type nAChRs. Indeed, we have shown that [3 H]- or [125 I]-epibatidine can be used to measure at least seven different nAChR subtypes (see Figure 2) [10,70,84,85]. These subtypes can be distinguished from one another on the basis of affinity for epibatidine (higher and lower affinity sites have been detected) and sensitivity to inhibition by other nicotinic compounds; e.g. cytisine is especially useful for distinguishing two subsets of higher affinity [3 H]-epibatidine binding sites. A85380 distinguishes between $\beta 2^*$ and $\beta 4^*$ nAChRs, and α -bungarotoxin is useful for distinguishing at least two classes of lower affinity binding sites.

The upper panel of Figure 3 presents the results of experiments that evaluated the effects of $\alpha 4$, $\alpha 5$, $\alpha 7$, $\beta 2$, $\beta 3$ and $\beta 4$ gene deletion on the cytisine-sensitive component of higher affinity [3 H]-epibatidine binding [70]. Striatal tissue was used for the studies described here because a primary goal of these studies is to identify the nAChR subtypes that are expressed in dopaminergic nerve terminals. As is evident from the results presented in Figure 3, both $\alpha 4$ and $\beta 2$ gene deletion resulted in total elimination of cytisine-sensitive [3 H]-epibatidine binding ($\alpha 4\beta 2^*$). Binding in heterozygous (+/-) mice was decreased by approximately 40%; i.e. a gene dose dependent decrease in binding was seen. The finding that $\alpha 4$ and $\beta 2$ subunits are required to form the cytisine-sensitive high affinity [3 H]-epibatidine binding sites mimic exactly that obtained with [3 H]-nicotine [71,72] and clearly demonstrate that $\alpha 4\beta 2^*$ nAChRs are expressed in the striatum. Deletion of the $\alpha 5$, $\alpha 6$, $\alpha 7$, $\beta 3$ and $\beta 4$ subunits did not result in a detectable change in cytisine-sensitive [3 H]-epibatidine binding.

We have also evaluated the effects of $\alpha 4$, $\alpha 5$, $\alpha 7$, $\beta 2$, $\beta 3$ and $\beta 4$ gene deletion on [125 I]- α -CtxMII ($\alpha 6\beta 2^*$) binding in striatal membranes [86]. Deletion of the $\alpha 4$ and $\beta 3$ subunits resulted in significant, but not total, elimination of [125 I]- α -CtxMII binding (lower panel of Figure 3). These results suggest that at least some of the nAChRs that bind [125 I]- α -CtxMII with high affinity require these subunits for their formation. Binding was nearly absent in striatal tissues obtained from $\beta 2$ null mutants. We suspect that $\beta 2$ deletion results in total elimination of

[¹²⁵I]- α -CtxMII binding-nAChRs, but we cannot be totally confident that this conclusion is accurate because this assay is plagued by high nonspecific binding [86]. Deletion of the α 5, α 7, and β 4 subunits did not result in any detectable changes in binding.

Expression of nAChRs in *Xenopus laevis* has shown that α -CtxMII binds with high affinity to α 3 β 2* nAChRs [82] and α 6 β 2* nAChRs [33]. However, deletion of nAChR subunits clearly demonstrated that α 6 is required to form those nAChRs that bind [¹²⁵I]- α -CtxMII with high affinity in dopaminergic neurons whereas α 3 is not. Specifically, null mutation of the α 6 subunit results in a total elimination of [¹²⁵I]- α -CtxMII binding in dopaminergic pathways [87] whereas null mutation of the α 3 gene has no effect [88]. The observation that α 3 gene deletion results in total elimination of [¹²⁵I]- α -CtxMII binding in a few brain regions (e.g. medial habenula, fasciculus retroflexus) and marked reductions in others (e.g. interpeduncular nucleus) clearly demonstrates that at least some native α 3-containing nAChRs will bind [¹²⁵I]- α -CtxMII with moderate to moderate affinity. Thus, even though α 3 mRNA is expressed in some SN and VTA dopaminergic cell bodies, α 3-containing nAChRs that bind [¹²⁵I]- α -CtxMII with at least moderate affinity may not be formed in these brain regions or not axonally transported to dopaminergic terminals. Taken together, these results argue that α 6, rather than α 3, partners with β 2 to form all of the nAChRs that bind [¹²⁵I]- α -CtxMII with high affinity, but moderate affinity binding may occur at α 3 β 2* mouse nAChRs. The findings that α 4 and β 3 gene deletion result in partial decreases in [¹²⁵I]- α -CtxMII binding indicates that about half of the α 6 β 2* nAChRs include the α 4 subunit and approximately 2/3 include the β 3 subunit. However, while it is clear that striatal tissue expresses nAChRs on dopaminergic nerve terminals [41,89,90], it is also readily apparent that other neurons, particularly GABAergic nerve terminals [47] also express nAChRs. Perhaps the best support for this assertion comes from the finding that approximately 50% of total epibatidine binding persists in mouse striatal tissue following treatment with MPTP doses that virtually eliminate [¹²⁵I]- α -CtxMII binding, dopamine transporters and nicotine-stimulated [³H]-dopamine release, without affecting nicotine-stimulated [³H]-GABA release from striatal synaptosomes [91]. It seems highly likely that α -CtxMII-binding nAChRs are expressed almost exclusively in dopaminergic neurons, given that treatment with the dopamine neuron neurotoxin, MPTP, results in decreases in mouse striatal [¹²⁵I]- α -CtxMII binding that closely parallel declines in the dopamine transporter and agonist-induced dopamine release without affecting GABA markers [91].

Failure to detect an effect of gene deletion on binding must be interpreted cautiously. For example, α 5, α 7, β 3 and β 4 gene deletion did not produce a measurable effect on cytosine-sensitive [³H]-epibatidine and deletion of the α 5, α 7 and β 4 subunits did not affect [¹²⁵I]- α -CtxMII binding, which may indicate that none of these subunits are absolutely required to form these receptors. It should be noted, however, that gene deletion may not elicit a detectable change in ligand binding if a neuron makes an alternative receptor (eg. α 4 β 2) where it normally might make an α 4 α 5 β 2 nAChR.. Other methods may be necessary to resolve this issue.

Immunological approaches have also been used to investigate nAChR subtypes that are expressed in mouse striatum. These methods can help verify which subunits combine to form a receptor subtype. Champiaux et al. [41] used antibodies that were directed against the rat and human α 4- α 7, and β 2- β 4 subunits in immunoprecipitation experiments and identified three heteromeric receptors α 4 β 2*, α 6 α 4 β 2* and α 6 β 2* in striatum. More recently, Gotti et al. [92] used the same battery of subunit specific antibodies to measure the nAChR subtypes that are expressed in wild type and β 3 null mutant striata. Three α 6* nAChR subtypes (α 4 α 6 β 2 β 3, α 6 β 2 β 3, and a low concentration of α 6 β 2) were identified. These α 6* subtypes are, presumably, the nAChRs that bind [¹²⁵I]- α -CtxMII with high affinity. Comparable studies done with the rat identified α 4 α 5 β 2, α 4 α 6 β 2(β 3) and α 6 β 2(β 3) nAChRs in striatum (the (β 3) designation was used to indicate the possible presence of the β 3 subunit) [93]. Thus, immunological approaches indicate that a minimum of five nAChR subtypes (α 4 β 2, α 4 α 5 β 2, α 4 α 6 β 2 β 3, α 6 β 2 β 3 and

$\alpha 6\beta 2$) are expressed in rodent striatum. The likelihood that expressing multiple nicotinic receptors in dopaminergic nerve terminals is biologically important is enhanced by the findings that immunological methods have identified the same receptors in striatal tissue obtained from squirrel monkeys [94] and humans [95].

The subunit composition of nAChRs, expressed in *Xenopus laevis* oocytes, has profound effects on biophysical (channel open time, ion conductance, desensitization rates) and pharmacological (sensitivity to agonists and antagonists) properties of nAChRs [31,32,96]. These findings have prompted several research groups, including ours, to develop biochemical methods that might be used to characterize the functional properties of native nAChRs. Nicotinic agonist-stimulated release of dopamine from brain has been studied intensively for over 40 years. Westfall [97] was the first to demonstrate nicotinic facilitation of dopamine release from rat brain striatal slices. Since that time, others have established that nicotine, and other nicotinic agonists, will elicit Ca^{++} -dependent release of dopamine from striatal tissue slices (see, for examples [98,99]) and synaptosomes [39]. We have used a variant of the synaptosomal dopamine release assay that was originally developed in the Wonnacott laboratory [39] in a series of studies that characterized the pharmacological properties of dopamine release from striatum [40,89,90,100,101,102], as well as in other brain regions such as the nucleus accumbens, olfactory tubercles and frontal cortex [103]. Dose-response curves for agonist-stimulated dopamine release were obtained with many agonists, and, without exception, the results suggested that dopamine release is modulated by a single receptor subtype. However, the finding that α -CtxMII is a potent, but partial, inhibitor of nicotinic agonist-stimulated [^3H]-dopamine release from rat striatal synaptosomes [104] argued that, in spite of the agonist data, more than one nAChR subtype might be expressed on striatal dopaminergic nerve terminals. This finding prompted us to determine whether α -CtxMII also inhibits nicotinic agonist-stimulated [^3H]-dopamine release from mouse striatal synaptosomes [103]. As was the case with the rat, α -CtxMII proved to be a partial inhibitor of ACh-stimulated [^3H]-dopamine release from mouse striatal synaptosomes (Figure 4A). Panel B of Figure 4 shows concentration-effect curves for ACh-stimulated [^3H]-dopamine release from untreated synaptosomes (total release) and synaptosomes that had been incubated with 30 nM α -CtxMII before perfusion (α -CtxMII-resistant release). The α -CtxMII-sensitive component was calculated by subtracting α -CtxMII-resistant release from total release. The α -CtxMII-sensitive component of ACh-stimulated dopamine release accounts for approximately 1/3 of total release and the α -CtxMII-resistant component is approximately 2/3 of total release.

The observation that α -CtxMII is a partial inhibitor of ACh-stimulated [^3H]-dopamine release was not surprising given that α -CtxMII binds with high affinity to $\alpha 3\beta 2^*$ and $\alpha 6\beta 2^*$ nAChRs, but not to $\alpha 2^*$, $\alpha 4\beta 2^*$ and $\alpha 7^*$ nAChRs, and that at least $\alpha 6^*$ and $\alpha 4\beta 2^*$ are found in striatum. We chose to explore the postulate that the α -CtxMII-sensitive and —resistant components of [^3H]-dopamine release are modulated by different nAChRs by examining the pharmacological properties of the α -CtxMII-sensitive and —resistant components of the release process. Panel C of Figure 4 illustrates the effects of application of varying concentrations of the four agonists on the α -CtxMII-resistant component of [^3H]-dopamine release. The agonists differed in potency and efficacy. Epibatidine (EPI) was the most potent agonist ($\text{EC}_{50} = 12 \text{ nM}$) followed by cytosine (CYT) ($\text{EC}_{50} = 470 \text{ nM}$), ACh ($\text{EC}_{50} = 1.02 \text{ }\mu\text{M}$) and nicotine (NIC) ($\text{EC}_{50} = 1.61 \text{ }\mu\text{M}$). The agonists also differed in maximal release (efficacy). Maximal release elicited by epibatidine was nearly four times that produced by cytosine and approximately 50% greater than the maximal release elicited by ACh and nicotine. Studies using expression systems have repeatedly demonstrated that cytosine has very low efficacy at $\alpha 4\beta 2^*$ nAChRs [31,105,106]. Consequently, the finding that the maximal [^3H]-dopamine release elicited by cytosine is very low when compared with other agonists suggests that the α -CtxMII-resistant component of nicotinic agonist-stimulated dopamine release is modulated by an $\alpha 4\beta 2^*$ nAChR. This conclusion is consistent with the observation (see Panel A, Figure 3) that striatal membranes

express high levels of cytosine-sensitive [^3H]-epibatidine binding which requires $\alpha 4$ and $\beta 2$ subunits.

The effects of varying agonist concentrations on the αCtxMII -sensitive component of [^3H]-dopamine release are provided in Panel D of Figure 4. Once again, epibatidine was the most potent agonist ($\text{EC}_{50} = 780 \text{ pM}$). The rank order of potencies (EC_{50} values) for the other three agonists is: cytosine (31 nM), ACh (150 nM) and nicotine (770 nM). This rank order differed from the results obtained with the αCtxMII -resistant component of dopamine release. Differences between the agonists in efficacy were also observed, but these differences were not robust. Once again, epibatidine elicited the greatest maximal response, but robust differences in efficacy were not seen for the other three agonists. These findings argue that the αCtxMII -sensitive component of agonist-elicited [^3H]-dopamine release is modulated by a different receptor(s) than is the αCtxMII -resistant response. Moreover, these results demonstrate that those nAChRs that modulate the αCtxMII -sensitive component of dopamine release are frequently more sensitive to the agonist properties of nicotinic ligands. This result is somewhat surprising since $\alpha 4\beta 2^*$ nAChRs has the highest affinities in binding experiments.

Studies done with nicotinic antagonists provide further support for the conclusion that different nAChRs modulate the αCtxMII -sensitive and —resistant components of dopamine release. Panel E of Figure 4 shows that methyllycaconitine (MLA) pretreatment totally blocks both the αCtxMII -sensitive and —resistant components of agonist-stimulated dopamine release. The IC_{50} value for inhibition of the αCtxMII -sensitive component is approximately $0.5 \mu\text{M}$ whereas the IC_{50} for inhibition of the αCtxMII -resistant component is approximately $10 \mu\text{M}$. Panel F of Figure 4 depicts results obtained when the actions of dihydro- β -erythroidine (DH β E) were evaluated. DH β E pretreatment produced total blockade of agonist-stimulated dopamine release, but, in this case, the αCtxMII -resistant component was more sensitive to inhibition than was αCtxMII -sensitive component (IC_{50} values = $.06 \mu\text{M}$ [αCtxMII -resistant] and $0.9 \mu\text{M}$ [αCtxMII -sensitive]).

Figure 5 presents the results of experiments that evaluated the effects of deleting the $\alpha 2$, $\alpha 4$, $\alpha 5$, $\alpha 7$, $\beta 2$, $\beta 3$ and $\beta 4$ genes on ACh-stimulated ($10 \mu\text{M}$) [^3H]-dopamine release from striatal synaptosomes. Panel A provides the results obtained when αCtxMII -resistant dopamine release was measured. Deletion of the $\alpha 2$, $\alpha 7$ and $\beta 4$ genes had no discernable effect. In contrast, $\alpha 4$ and $\beta 2$ gene deletion resulted in total elimination of this component of dopamine release. These results indicate that the αCtxMII -resistant component of dopamine release is modulated by an $\alpha 4\beta 2^*$ nAChR. These results are also consistent with the finding that deleting these genes resulted in the total loss of cytosine-sensitive [^3H]-epibatidine binding. Unlike binding, however, $\alpha 5$ gene deletion produced a significant decrease in the αCtxMII -resistant component of ACh-stimulated dopamine release. This finding argues that at least some of the nAChRs that modulate the αCtxMII -resistant component of dopamine release are $\alpha 4\alpha 5\beta 2$ nAChRs. A similar functional decrease, with no decrease in receptor number, is seen in the $\alpha 5$ null mutant mouse when function is measured by $^{86}\text{Rb}^+$ efflux [107]. Given that $\alpha 5$ gene deletion did not change cytosine-sensitive [^3H]-epibatidine binding (Figure 3), we suspect that both $\alpha 4\beta 2$ and $\alpha 4\alpha 5\beta 2$ nAChRs are normally expressed in striatal dopaminergic nerve terminals and that $\alpha 4\beta 2$ nAChRs replace the $\alpha 4\alpha 5\beta 2$ nAChRs in the $\alpha 5$ null mutant mice. It has been repeatedly demonstrated that $\alpha 4\beta 2$ nAChRs expressed in *Xenopus* oocytes or cultured cells can assemble in two stoichiometric forms with differing sensitivities to activation by agonists [108,109, 110]. In neurons there is evidence for two forms of $\alpha 4\beta 2$ receptors with functional differences [111, and MJ Marks, unpublished data]; however, these two forms may have similar binding affinities (MJ Marks, unpublished data). These properties of naturally occurring $\alpha 4\beta 2$ receptors could explain the discrepancy between binding and function seen in the $\alpha 5$ subunit null mutant mouse where high affinity ($\alpha 4\beta 2^*$) binding appears unchanged but the high affinity function is decreased.

Panel B of Figure 5 depicts the effects of gene deletion on the α CtxMII-sensitive component of [3 H]-dopamine release. Once again, $\alpha 2$, $\alpha 7$ and $\beta 4$ gene deletion produced no discernable effect. $\beta 2$ gene deletion resulted in total elimination of this component of dopamine release, a finding that exactly mirrors the observation that $\alpha 6$ gene deletion eliminates α CtxMII-sensitive dopamine release [41] indicating that all of the nAChRs that modulate the α CtxMII-sensitive component of dopamine release are $\alpha 6\beta 2^*$. Both $\alpha 4$ and $\beta 3$ gene deletion resulted in partial reductions in α CtxMII-sensitive release, consistent with the immunological results that indicate that $\alpha 4\alpha 6\beta 2\beta 3$ and $\alpha 6\beta 2\beta 3$ nAChRs are expressed in mouse striatum.

Gene deletion did not always result in a decrease in agonist-stimulated [3 H]-dopamine release. Deleting the $\beta 3$ gene resulted in an unexpected increase in the α CtxMII-resistant component of ACh-stimulated dopamine release. This increase was not accompanied by a discernable change in cytosine-sensitive [3 H]-epibatidine binding (Figure 3) or in a detectable change in brain mRNA concentrations for any of the other subunits ($\alpha 2$ - $\alpha 7$, $\beta 2$, $\beta 4$) that are normally expressed in mouse brain [100]. Thus, $\beta 3$ gene deletion elicited an increase in a response that appears to be modulated by $\alpha 4(\alpha 5)\beta 2$ nAChRs, but it did not change the number of receptors that are measured by a binding assay that requires expression of $\alpha 4$ and $\beta 2$ subunits. Similar findings were obtained when the effects of $\alpha 5$ gene deletion were evaluated. Deleting the $\alpha 5$ gene resulted in an increase in α -CtxMII-sensitive dopamine release, but $\alpha 5$ gene deletion did not produce a detectable change in [125 I]- α -CtxMII binding (Figure 3). In both cases, as expected, gene deletion resulted in loss of function for those components of dopamine release that are modulated by receptors that normally include the deleted subunit gene (see Figure 5). Unexpectedly, in both cases, a compensatory biochemical increase in release is seen in that component modulated by receptors that do not contain the deleted gene product (see Figure 5). These biochemical compensations occur without detectable alterations in the number of receptors.

As indicated previously, nAChRs are expressed on cell bodies, dendrites, and axons, as well as close to and at the nerve terminal [30]. A series of studies have attempted to evaluate which of these expression sites is most important in regulating dopamine release and conflicting results have been obtained. Several studies [112,113,114] yielded results that questioned whether presynaptic nAChRs expressed in the nerve terminals play a role in regulating dopamine release. All of these studies evaluated the effects of systemic nicotine injection on dopamine release in the rat nucleus accumbens using *in vivo* microdialysis and all of these studies showed that inhibiting nAChRs expressed on cell bodies, or blocking action potentials with tetrodotoxin, resulted in virtual elimination of nicotine-induced dopamine release in the accumbens. Other studies that evaluated the effects of nicotine infused into dopaminergic nerve terminals (accumbens, striatum, frontal cortex) resulted in readily detected increases in dopamine release [115,116]. These contradictory findings might be explained by the more recent observation that used cyclic voltametry to obtain a better resolution of time-dependent effects of nicotine application on dopamine release. The data obtained using striatal [117] and nucleus accumbens [118] slices are identical: nicotine produces a decrease in dopamine release following a single electrical stimulation and an increase in release following a burst of five stimulations. These observations argue that both somatodendritic and nerve terminal nAChRs play important roles in modulating the release of dopamine from dopaminergic neurons.

In summary, the studies outlined here demonstrate that dopaminergic nerve terminals in the striatum express as many as five different nAChR subtypes ($\alpha 4\beta 2$, $\alpha 4\alpha 5\beta 2$, $\alpha 4\alpha 6\beta 2\beta 3$, $\alpha 6\beta 2\beta 3$ and $\alpha 6\beta 2$). It is not clear what advantages accrue from having so many subtypes expressed in dopaminergic nerve terminals. Perhaps multiple subtypes allow a very fine control of dopaminergic activity or perhaps different dopaminergic nerve terminals express different subtypes. For example, multiple subtypes could allow release differentially associated with voltage-sensitive calcium channels [38]. These questions have not been addressed, but our data

indicating that the $\alpha 4(\alpha 5)\beta 2$ and $\alpha 6\beta 2^*$ subtypes clearly have different pharmacological properties suggest that subtype selective compounds might be developed. Such compounds might result in more effective smoking-cessation therapies as well as treatments for psychopathologies and neurodegenerative diseases that involve the nigro-striatal dopamine system.

Acknowledgments

Supported by NIH grants DA03194 (ACC), DA015663 (ACC), DA12242 (MJM), DA019375 (MJM).

References

- [1]. Martin LF, Kem WR, Freedman R. Alpha-7 nicotinic receptor agonists: potential new candidates for the treatment of schizophrenia. *Psychopharmacology* 2004;174:54–64. [PubMed: 15205879]
- [2]. Singh A, Potter A, Newhouse P. Nicotinic acetylcholine receptor system and neuropsychiatric disorders. *Idrugs* 2004;7:1096–103. [PubMed: 15599803]
- [3]. Potter AS, Newhouse PA, Bucci DJ. Central nicotinic cholinergic systems: a role in the cognitive dysfunction in attention-deficit/hyperactivity disorder? *Behav Brain Research* 2006;175:201–11.
- [4]. Steinlein OK. Nicotinic receptor mutations in human epilepsy. *Prog in Brain Res* 2004;145:275–85. [PubMed: 14650922]
- [5]. Quik M, O'Neill M, Perez XA. Nicotine neuroprotection against nigrostriatal damage: importance of the animal model. *Trends in Pharmacol Sci* 2007;28:229–35. [PubMed: 17412429]
- [6]. Marks MJ, Collins AC. Characterization of nicotine binding in mouse brain and comparison with the binding of alpha-bungarotoxin and quinuclidinyl benzilate. *Mol Pharmacol* 1982;22:554–64. [PubMed: 7155123]
- [7]. Clarke PB, Pert CB, Pert A. Autoradiographic distribution of nicotine receptors in rat brain. *Brain Research* 1984;323:390–5. [PubMed: 6098346]
- [8]. Pauly JR, Stitzel JA, Marks MJ, Collins AC. An autoradiographic analysis of cholinergic receptors in mouse brain. *Brain Res Bull* 1989;22:453–9. [PubMed: 2706548]
- [9]. Perry DC, Kellar KJ. [3H]-epibatidine labels nicotinic receptors in rat brain: an autoradiographic study. *J Pharm Exp Ther* 1995;275:1030–4.
- [10]. Whiteaker P, Jimenez M, McIntosh JM, Collins AC, Marks MJ. Identification of a novel nicotinic binding site in mouse brain using [(125)I]-epibatidine. *Brit J Pharmacol* 2000;131:729–39. [PubMed: 11030722]
- [11]. Gould TJ, Wehner JM. Nicotine enhancement of contextual fear conditioning. *Behav Brain Res* 1999;102:31–9. [PubMed: 10403013]
- [12]. Caldarone BJ, Duman CH, Picciotto MR. Fear conditioning and latent inhibition in mice lacking the high affinity subclass of nicotinic acetylcholine receptors in the brain. *Neuropharmacology* 2000;39:2779–84. [PubMed: 11044747]
- [13]. Levin ED, McClernon FJ, Rezvani AH. Nicotinic effects on cognitive function, behavioral characterization, pharmacological specification, and anatomical localization. *Psychopharmacol* 2006;184:523–9.
- [14]. Irvine EE, Cheeta S, File SE. Time-course of changes in the social interaction test of anxiety following acute and chronic administration of nicotine. *Behav Pharmacol* 1999;10:691–7. [PubMed: 10780511]
- [15]. Aceto MD, Awaya H, Martin BR, May EL. Antinociceptive action of nicotine and its methiodide derivatives in mice and rats. *Brit J Pharm* 1983;79:869–76.
- [16]. Damaj MI, Welch SP, Martin BR. Involvement of calcium and L-type channels in nicotine-induced antinociception. *J Pharm Exp Ther* 1993;266:1330–8.
- [17]. Hatchell PC, Collins AC. The influence of genotype and sex on behavioral sensitivity to nicotine in mice. *Psychopharmacology* 1980;71:45–9. [PubMed: 6779324]
- [18]. Stolerman IP, Garcha HS, Mirza NR. Dissociations between the locomotor stimulant and depressant effects of nicotinic agonists in rats. *Psychopharmacology*, 1995;117(4):430–7. [PubMed: 7604144]

- [19]. Khwaja M, McCormack A, McIntosh JM, Di Monte DA, Quik M. Nicotine partially protects against paraquat-induced nigrostriatal damage in mice; link to $\alpha 6 \beta 2^*$ nAChRs. *J Neurochem* 2007;100:180–90. [PubMed: 17227438]
- [20]. Tizabi Y, Al-Namaeh M, Manaye KF, Taylor RE. Protective effects of nicotine on ethanol-induced toxicity in cultured cerebellar granule cells. *Neurotoxicity Res* 2003;5:315–21.
- [21]. Hejmadi MV, Dajas-Bailador F, Barns SM, Jones B, Wonnacott S. Neuroprotection by nicotine against hypoxia-induced apoptosis in cortical cultures involves activation of multiple nicotinic acetylcholine receptor subtypes. *Mol Cell Neurosci* 2003;24:779–86. [PubMed: 14664825]
- [22]. Stevens TR, Krueger SR, Fitzsimonds RM, Picciotto MR. Neuroprotection by nicotine in mouse primary cortical cultures involves activation of calcineurin and L-type calcium channel inactivation. *J Neurosci* 2003;23:10093–9. [PubMed: 14602824]
- [23]. Marks MJ, Stitzel JA, Collins AC. Genetic influences on nicotine responses. *Pharmacol Biochem Behav* 1989;33:667–78. [PubMed: 2587608]
- [24]. Hanna ST. Nicotine effect on cardiovascular system and ion channels. *J Cardiovascular Pharmacol* 2006;47:348–58.
- [25]. Wang N, Orr-Urtreger A, Chapman J, Rabinowitz R, Korczyn AD. Deficiency of nicotinic acetylcholine receptor beta 4 subunit causes autonomic cardiac and intestinal dysfunction. *Mol Pharmacol* 2003;63:574–80. [PubMed: 12606764]
- [26]. Miner LL, Collins AC. Strain comparison of nicotine-induced seizure sensitivity and nicotinic receptors. *Pharmacol Biochem Behav* 1989;33:469–75. [PubMed: 2813485]
- [27]. Damaj MI, Glassco W, Dukat M, Martin BR. Pharmacological characterization of nicotine-induced seizures in mice. *J Pharmacol Exp Ther* 1999;291:1284–91. [PubMed: 10565853]
- [28]. Cooper E, Couturier S, Ballivet M. Pentameric structure and subunit stoichiometry of a neuronal nicotinic acetylcholine receptor. *Nature* 1991;350:235–8. [PubMed: 2005979]
- [29]. Leonard S, Bertrand D. Neuronal nicotinic receptors: from structure to function. *Nicotine & Tobacco Res* 2001;3:203–23.
- [30]. Dani JA, Bertrand D. Nicotinic acetylcholine receptors and nicotinic cholinergic mechanisms of the central nervous system. *Ann Rev Pharm & Toxicol* 2007;47:699–729.
- [31]. Luetje CW, Patrick J. Both alpha- and beta-subunits contribute to the agonist sensitivity of neuronal nicotinic acetylcholine receptors. *J Neurosci* 1991;11:837–45. [PubMed: 1705971]
- [32]. Harvey SC, Luetje CW. Determinants of competitive antagonist sensitivity on neuronal nicotinic receptor beta subunits. *J Neurosci* 1996;16:3798–806. [PubMed: 8656274]
- [33]. Kuryatov A, Olale FA, Choi C, Lindstrom J. Acetylcholine receptor extracellular domain determines sensitivity to nicotine-induced inactivation. *Eur J Pharmacol* 2000;393:11–21. [PubMed: 10770993]
- [34]. Rush R, Kuryatov A, Nelson ME, Lindstrom J. First and second transmembrane segments of $\alpha 3$, $\alpha 4$, $\beta 2$, and $\beta 4$ nicotinic acetylcholine receptor subunits influence the efficacy and potency of nicotine. *Mol Pharm* 2002;61:1416–22.
- [35]. Wonnacott S. Presynaptic nicotinic ACh receptors. *Trends in Neurosci* 1997;20:92–8.
- [36]. Dajas-Bailador F, Wonnacott S. Nicotinic acetylcholine receptors and the regulation of neuronal signalling. *Trends in Pharmacol Sci* 2004;25:317–24. [PubMed: 15165747]
- [37]. Gotti C, Zoli M, Clementi F. Brain nicotinic acetylcholine receptors: native subtypes and their relevance. *Trends in Pharmacol Sci* 2006;27:482–91. [PubMed: 16876883]
- [38]. Kulak JM, McIntosh JM, Yoshikami D, Olivera BM. Nicotine-evoked transmitter release from synaptosomes: functional association of specific presynaptic acetylcholine receptors and voltage-gated calcium channels. *J Neurochem* 2001;77:1581–9. [PubMed: 11413241]
- [39]. Rapier C, Lunt GG, Wonnacott S. Stereoselective nicotine-induced release of dopamine from striatal synaptosomes: concentration dependence and repetitive stimulation. *J Neurochem* 1988;50:1123–30. [PubMed: 3346670]
- [40]. Grady S, Marks MJ, Wonnacott S, Collins AC. Characterization of nicotinic receptor-mediated [3 H] dopamine release from synaptosomes prepared from mouse striatum. *J Neurochem* 1992;59:848–56. [PubMed: 1494911]

- [41]. Champtiaux N, Gotti C, Cordero-Erausquin M, David DJ, Przybylski C, Lena C. Subunit composition of functional nicotinic receptors in dopaminergic neurons investigated with knockout mice. *J Neurosci* 2003;23:7820–9. [PubMed: 12944511]
- [42]. Salminen O, Murphy KL, McIntosh JM, Drago J, Marks MJ, Collins AC, Grady SR. Subunit composition and pharmacology of two classes of striatal presynaptic nicotinic acetylcholine receptors mediating dopamine release in mice. *Mol Pharmacol* 2004;65:1526–35. [PubMed: 15155845]
- [43]. Clarke PB, Reuben M. Release of [3H]-noradrenaline from rat hippocampal synaptosomes by nicotine: mediation by different nicotinic receptor subtypes from striatal [3H]-dopamine release. *Brit J Pharmacol* 1996;117:595–606. [PubMed: 8646402]
- [44]. Azam L, McIntosh JM. Characterization of nicotinic acetylcholine receptors that modulate nicotine-evoked [3H]norepinephrine release from mouse hippocampal synaptosomes. *Mol Pharmacol* 2006;70:967–76. [PubMed: 16735605]
- [45]. Kaiser S, Wonnacott S. alpha-bungarotoxin-sensitive nicotinic receptors indirectly modulate [(3)H]dopamine release in rat striatal slices via glutamate release. *Mol Pharmacol* 2000;58:312–8. [PubMed: 10908298]
- [46]. Sharma G, Vijayaraghavan S. Modulation of presynaptic store calcium induces release of glutamate and postsynaptic firing. *Neuron* 2003;38:929–39. [PubMed: 12818178]
- [47]. Lu Y, Grady S, Marks MJ, Picciotto M, Changeux JP, Collins AC. Pharmacological characterization of nicotinic receptor-stimulated GABA release from mouse brain synaptosomes. *J Pharm Exp Ther* 1998;287:648–57.
- [48]. Wilkie GI, Hutson P, Sullivan JP, Wonnacott S. Pharmacological characterization of a nicotinic autoreceptor in rat hippocampal synaptosomes. *Neurochem Res* 1996;21:1141–8. [PubMed: 8897478]
- [49]. Grady SR, Meinerz NM, Cao J, Reynolds AM, Picciotto MR, Changeux JP, et al. Nicotinic agonists stimulate acetylcholine release from mouse interpeduncular nucleus: a function mediated by a different nAChR than dopamine release from striatum. *J Neurochem* 2001;76:258–68. [PubMed: 11145999]
- [50]. Corrigall WA, Franklin KB, Coen KM, Clarke PB. The mesolimbic dopaminergic system is implicated in the reinforcing effects of nicotine. *Psychopharmacology* 1992;107:285–9. [PubMed: 1615127]
- [51]. Balfour DJ, Benwell ME, Birrell CE, Kelly RJ, Al-Aloul M. Sensitization of the mesoaccumbens dopamine response to nicotine. *Pharmacol Biochem Behav* 1998;59:1021–30. [PubMed: 9586863]
- [52]. Rahman S, Zhang J, Engleman EA, Corrigall WA. Neuroadaptive changes in the mesoaccumbens dopamine system after chronic nicotine self-administration: a microdialysis study. *Neuroscience* 2004;129:415–24. [PubMed: 15501598]
- [53]. Quik M, McIntosh JM. Striatal alpha6* nicotinic acetylcholine receptors: potential targets for Parkinson's disease therapy. *J Pharmacol Exp Ther* 2006;316:481–9. [PubMed: 16210393]
- [54]. Levin ED, McGurk SR, Rose JE, Butcher LL. Cholinergic-dopaminergic interactions in cognitive performance. *Behav Neural Biol* 1990;54:271–99. [PubMed: 2078161]
- [55]. Brioni JD, Arneric SP. Nicotinic receptor agonists facilitate retention of avoidance training: participation of dopaminergic mechanisms. *Behav Neural Biol* 1993;59(1):57–62. [PubMed: 8442733]
- [56]. File SE, Kenny PJ, Ouagazzal AM. Bimodal modulation by nicotine of anxiety in the social interaction test: role of the dorsal hippocampus. *Behav Neurosci* 1998;112(6):1423–9. [PubMed: 9926824]
- [57]. Morissette SB, Tull MT, Gulliver SB, Kamholz BW, Zimering RT. Anxiety, anxiety disorders, tobacco use, and nicotine: a critical review of interrelationships. *Psychol Bull* 2007;133:245–72. [PubMed: 17338599]
- [58]. Benwell ME, Balfour DJ. The effects of acute and repeated nicotine treatment on nucleus accumbens dopamine and locomotor activity. *Brit J Pharmacol* 1992;105:849–56. [PubMed: 1504716]
- [59]. Janhunen S, Linnervuo A, Svensk M, Ahthe L. Effects of nicotine and epibatidine on locomotor activity and conditioned place preference in rats. *Pharmacol Biochem Behav* 2005;82:758–65. [PubMed: 16413603]

- [60]. de Leon J, Diaz FJ. A meta-analysis of worldwide studies demonstrates an association between schizophrenia and tobacco smoking behaviors. *Schizophrenia Res* 2005;76:135–57.
- [61]. Pomerleau CS, Downey KK, Snedecor SM, Mehringer AM, Marks JL, Pomerleau OF. Smoking patterns and abstinence effects in smokers with no ADHD, childhood ADHD and adult ADHD symptomatology. *Addiction Behav* 2003;28:1149–57.
- [62]. Allam MF, Campbell MJ, Hofman A, Del Castillo AS, Navajas R Fernandez-Crehuet. Smoking and Parkinson's disease: systematic review of prospective studies. *Movement Disorders* 2004;19:614–21. [PubMed: 15197698]
- [63]. Salminen O, Drapeau J, McIntosh JM, Collins AC, Marks MJ, Grady SR. Pharmacology of α -conotoxin MII-sensitive subtypes of nicotinic acetylcholine receptors isolated by breeding of null mutant mice. *Mol Pharmacol*. 2007[Epub ahead of print]
- [64]. Marks MJ, Pauly JR, Gross SD, Deneris ES, Hermans-Borgmeyer I, Heinemann SF, Collins AC. Nicotine binding and nicotinic receptor subunit RNA after chronic nicotine treatment. *J Neurosci* 1992;12:2765–84. [PubMed: 1613557]
- [65]. Le Novère N, Zoli M, Changeux JP. Neuronal nicotinic receptor $\alpha 6$ subunit mRNA is selectively concentrated in catecholaminergic nuclei of the rat brain. *Eur J Neurosci* 1996;8:2428–39. [PubMed: 8950106]
- [66]. Azam L, Winzer-Serhan UH, Chen Y, Leslie FM. Expression of neuronal nicotinic acetylcholine receptor subunit mRNAs within midbrain dopamine neurons. *J Comp Neurol* 2002;444:260–74. [PubMed: 11840479]
- [67]. Klink R, de Kerchove d'Exaerde A, Zoli M, Changeux JP. Molecular and physiological diversity of nicotinic acetylcholine receptors in the midbrain dopaminergic nuclei. *J Neurosci* 2001;21:1452–63. [PubMed: 11222635]
- [68]. Salvaterra PM, Moore WJ. Binding of (125I)- α bungarotoxin to particulate fractions of rat and guinea pig brain. *Biochem Biophys Res Comm* 1973;55:1311–8. [PubMed: 4771998]
- [69]. Romano C, Goldstein A. Stereospecific nicotine receptors on rat brain membranes. *Science* 1980;210:647–50. [PubMed: 7433991]
- [70]. Marks MJ, Whiteaker P, Collins AC. Deletion of the $\alpha 7$, $\beta 2$, or $\beta 4$ nicotinic receptor subunit genes identifies highly expressed subtypes with relatively low affinity for [3H]epibatidine. *Mol Pharmacol* 2006;70:947–59. [PubMed: 16728647]
- [71]. Marubio LM, del Mar Arroyo-Jimenez M, Cordero-Erausquin M, Lena C, Le Novère N, de Kerchove d'Exaerde A, et al. Reduced antinociception in mice lacking neuronal nicotinic receptor subunits. *Nature* 1999;398:805–10. [PubMed: 10235262]
- [72]. Picciotto MR, Zoli M, Lena C, Bessis A, Lallemand Y, Le Novère N, et al. Abnormal avoidance learning in mice lacking functional high-affinity nicotine receptor in the brain. *Nature* 1995;374:65–7. [PubMed: 7870173]
- [73]. Pabreza LA, Dhawan S, Kellar KJ. [3H]Cytisine binding to nicotinic cholinergic receptors in brain. *Mol Pharmacol* 1991;39:9–12. [PubMed: 1987453]
- [74]. Schwartz RD, Lehmann J, Kellar KJ. Presynaptic nicotinic cholinergic receptors labeled by [3H]acetylcholine in rat brain. *Mol Pharmacol* 1982;22:56–62. [PubMed: 7121451]
- [75]. Clarke PBS, Schwartz RD, Paul SM, Pert CB, Pert A. Nicotinic binding in rat brain: autoradiographic comparison of [3H]acetylcholine, [3H]nicotine, and [125I]- α -bungarotoxin. *J Neurosci* 1985;5:1307–15. [PubMed: 3998824]
- [76]. Marks MJ, Stitzel JA, Romm E, Wehner JM, Collins AC. Nicotinic binding sites in rat and mouse brain: comparison of acetylcholine, nicotine and α -bungarotoxin. *Mol Pharmacol* 1986;30:427–36. [PubMed: 3534542]
- [77]. Martino-Barrows AM, Kellar KJ. [3H]Acetylcholine and [3H](–)nicotine label the same recognition site in rat brain. *Mol Pharmacol* 1987;31:169–74. [PubMed: 3807893]
- [78]. Whiting PJ, Lindstrom J. Characterization of bovine and human neuronal nicotinic acetylcholine receptors using monoclonal antibodies. *J Neurosci* 1988;8:3395–404. [PubMed: 3171681]
- [79]. Flores CM, Rogers SW, Pabreza LA, Wolfe BB, Kellar KJ. A subtype of nicotinic cholinergic receptor in rat brain is composed of $\alpha 4$ and $\beta 2$ subunits and is up-regulated by chronic nicotinic treatment. *Mol Pharmacol* 1992;41:31–7. [PubMed: 1732720]

- [80]. Badio B, Daly JW. Epibatidine, a potent analgetic and nicotinic agonist. *Mol Pharmacol* 1994;45:563–9. [PubMed: 8183234]
- [81]. Houghtling RA, Davila-Garcia MI, Kellar KJ. Characterization of (+/-) (-)[3H]-epibatidine binding to nicotinic cholinergic receptors in rat and human brain. *Mol Pharmacol* 1995;48:280–7. [PubMed: 7651361]
- [82]. Cartier GE, Yoshikami D, Gray WR, Luo S, Olivera BM, McIntosh JM. A new alpha-conotoxin which targets alpha3beta2 nicotinic acetylcholine receptors. *J Biol Chem* 1996;271:7522–8. [PubMed: 8631783]
- [83]. Whiteaker P, McIntosh JM, Luo S, Collins AC, Marks MJ. 125-I- α -Conotoxin MII identifies a novel nicotinic acetylcholine receptor population in mouse brain. *Mol Pharmacol* 2000;57:913–25. [PubMed: 10779374]
- [84]. Marks MJ, Whiteaker P, Grady SR, Picciotto MR, McIntosh JM, Collins AC. Characterization of [(125) I]epibatidine binding and nicotinic agonist-mediated (86) Rb(+) efflux in interpeduncular nucleus and inferior colliculus of beta2 null mutant mice. *J Neurochem* 2002;81:1102–15. [PubMed: 12065623]
- [85]. Marks MJ, Rowell PP, Cao JZ, Grady SR, McCallum SE, Collins AC. Subsets of acetylcholine-stimulated 86Rb+ efflux and [125I]-epibatidine binding sites in C57BL/6 mouse brain are differentially affected by chronic nicotine treatment. *Neuropharmacology* 2004;46:1141–57. [PubMed: 15111021]
- [86]. Salminen O, Whiteaker P, Grady SR, Collins AC, McIntosh JM, Marks MJ. The subunit composition and pharmacology of alpha-Conotoxin MII-binding nicotinic acetylcholine receptors studied by a novel membrane-binding assay. *Neuropharmacology* 2005;48:696–705. [PubMed: 15814104]
- [87]. Champiaux N, Han ZY, Bessis A, Rossi FM, Zoli M, Marubio L, et al. Distribution and pharmacology of alpha 6-containing nicotinic acetylcholine receptors analyzed with mutant mice. *J Neurosci* 2002;22:1208–17. [PubMed: 11850448]
- [88]. Whiteaker P, Peterson CG, Xu W, McIntosh JM, Paylor R, Beaudet AL, et al. Involvement of the alpha3 subunit in central nicotinic binding populations. *J Neurosci* 2002;22:2522–9. [PubMed: 11923417]
- [89]. Grady SR, Marks MJ, Collins AC. Desensitization of nicotine-stimulated [3H]dopamine release from mouse striatal synaptosomes. *J Neurochem* 1994;62:1390–8. [PubMed: 8133269]
- [90]. Grady SR, Grun EU, Marks MJ, Collins AC. Pharmacological comparison of transient and persistent [3H]dopamine release from mouse striatal synaptosomes and response to chronic L-nicotine treatment. *J Pharmacol Exp Ther* 1997;282:32–43. [PubMed: 9223537]
- [91]. Quik M, Sum JD, Whiteaker P, McCallum SE, Marks MJ, Musachio J, et al. Differential declines in striatal nicotinic receptor subtype function after nigrostriatal damage in mice. *Mol Pharmacol* 2003;63:1169–79. [PubMed: 12695545]
- [92]. Gotti C, Moretti M, Clementi F, Riganti L, McIntosh JM, Collins AC. Expression of nigrostriatal alpha 6-containing nicotinic acetylcholine receptors is selectively reduced, but not eliminated, by beta 3 subunit gene deletion. *Mol Pharmacol* 2005;67:2007–15. [PubMed: 15749993]
- [93]. Zoli M, Moretti M, Zanardi A, McIntosh JM, Clementi F, Gotti C. Identification of the nicotinic receptor subtypes expressed on dopaminergic terminals in the rat striatum. *J Neurosci* 2002;22:8785–9. [PubMed: 12388584]
- [94]. Quik M, Vailati S, Bordia T, Kulak JM, Fan H, McIntosh JM, et al. Subunit composition of nicotinic receptors in monkey striatum: effect of treatments with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine or L-DOPA. *Mol Pharmacol* 2005;67:32–41. [PubMed: 15470079]
- [95]. Gotti C, Moretti M, Bohr I, Ziabreva I, Vailati S, Renato L, et al. Selective nicotinic acetylcholine receptor subunit deficits identified in Alzheimer's disease, Parkinson's disease and dementia with Lewy bodies by immunoprecipitation. *Neurobiol Dis* 2006;23:481–9. [PubMed: 16759874]
- [96]. Papke RL, Boulter J, Patrick J, Heinemann S. Single-channel currents of rat neuronal nicotinic acetylcholine receptors expressed in *Xenopus* oocytes. *Neuron* 1989;3:589–96. [PubMed: 2484342]
- [97]. Westfall TC. Effect of nicotine and other drugs on the release of 3H-norepinephrine and 3H-dopamine from rat brain slices. *Neuropharmacology* 1974;13:693–700. [PubMed: 4216859]

- [98]. Giorguieff-Chesselet MF, Kemel ML, Wandscheer D, Glowinski J. Regulation of dopamine release by presynaptic nicotinic receptors in rat striatal slices: effect of nicotine in a low concentration. *Life Sciences* 1979;25:1257–62. [PubMed: 513957]
- [99]. Dwoskin LP, Buxton ST, Jewell AL, Crooks PA. S(-)-nornicotine increases dopamine release in a calcium-dependent manner from superfused rat striatal slices. *J Neurochem* 1993;60:2167–74. [PubMed: 8492124]
- [100]. Cui C, Booker TK, Allen RS, Grady SR, Whiteaker P, Marks MJ, et al. The beta3 nicotinic receptor subunit: a component of alpha-conotoxin MII-binding nicotinic acetylcholine receptors that modulate dopamine release and related behaviors. *J Neurosci* 2003;23:11045–53. [PubMed: 14657161]
- [101]. Sharples CG, Kaiser S, Soliakov L, Marks MJ, Collins AC, Washburn M, et al. UB-165: a novel nicotinic agonist with subtype selectivity implicates the alpha4beta2* subtype in the modulation of dopamine release from rat striatal synaptosomes. *J Neurosci* 2000;20:2783–91. [PubMed: 10751429]
- [102]. Whiteaker P, Marks MJ, Grady SR, Lu Y, Picciotto MR, Changeux JP, et al. Pharmacological and null mutation approaches reveal nicotinic receptor diversity. *Eur J Pharmacol* 2000;393:123–35. [PubMed: 10771005]
- [103]. Grady SR, Murphy KL, Cao J, Marks MJ, McIntosh JM, Collins AC. Characterization of nicotinic agonist-induced [(3)H]dopamine release from synaptosomes prepared from four mouse brain regions. *J Pharmacol Exp Ther* 2002;301:651–60. [PubMed: 11961070]
- [104]. Kulak JM, Nguyen TA, Olivera BM, McIntosh JM. Alpha-conotoxin MII blocks nicotine-stimulated dopamine release in rat striatal synaptosomes. *J Neurosci* 1997;17:5263–70. [PubMed: 9204910]
- [105]. Papke RL, Heinemann SF. Partial agonist properties of cytosine on neuronal nicotinic receptors containing the beta 2 subunit. *Mol Pharmacol* 1994;45:142–9. [PubMed: 8302273]
- [106]. Parker MJ, Beck A, Luetje CW. Neuronal nicotinic receptor beta2 and beta4 subunits confer large differences in agonist binding affinity. *Mol Pharmacol* 1998;54:1132–9. [PubMed: 9855644]
- [107]. Brown R, Collins AC, Lindstrom JM, Whiteaker P. Nicotinic $\alpha 5$ subunit deletion locally reduces high-affinity agonist activation without altering receptor numbers. *J Neurochem*. 2007in press
- [108]. Zwart R, Vijverberg HPM. Four pharmacologically distinct subtypes of $\alpha 4 \beta 2$ nicotinic acetylcholine receptor expressed in *Xenopus laevis* oocytes. *Mol Pharmacol* 1998;54:1124–31. [PubMed: 9855643]
- [109]. Nelson ME, Kuryatov A, Choi CH, Zhou Y, Lindstrom J. Alternate stoichiometries of $\alpha 4 \beta 2$ nicotinic acetylcholine receptors. *Mol Pharmacol* 2003;63:332–41. [PubMed: 12527804]
- [110]. Zhou Y, Nelson ME, Kuryatov A, Choi C, Cooper J, Lindstrom J. Human $\alpha 4 \beta 2$ acetylcholine receptors formed from linked subunits. *J Neurosci* 2003;23:9004–15. [PubMed: 14534234]
- [111]. Marks MJ, Whiteaker P, Calcaterra J, Stitzel JA, Bullock AE, Grady SR, et al. Two pharmacologically distinct components of nicotinic receptor-mediated rubidium efflux in mouse brain require the $\beta 2$ subunit. *J Pharmacol Exp Ther* 1999;289:1090–103. [PubMed: 10215692]
- [112]. Benwell MEM, Balfour DJK, Lucchi HM. Influence of tetrodotoxin and calcium on changes in extracellular dopamine levels evoked by systemic nicotine. *Psychopharmacol* 1993;112:467–74.
- [113]. Nisell M, Nomikos GG, Svensson TH. Systemic nicotine-induced dopamine release in the rat nucleus accumbens is regulated by nicotinic receptors in the ventral tegmental area. *Synapse* 1994;16:36–44. [PubMed: 8134899]
- [114]. Fu Y, Matta SG, Gao W, Brower VG, Sharp BM. Systemic nicotine stimulates dopamine release in nucleus accumbens: Re-evaluation of the role of N-methyl-D-aspartate receptors in the ventral tegmental area. *J Pharmacol Exp Ther* 2000;294:458–65. [PubMed: 10900219]
- [115]. Toth E, Sershen H, Hashim A, Visi ES, Lajtha A. Effect of nicotine on extracellular levels of neurotransmitters assessed by microdialysis in various brain regions: role of glutamic acid. *Neurochem Res* 1992;17:265–71. [PubMed: 1352387]
- [116]. Marshall DL, Redfern PH, Wonnacott S. Presynaptic nicotinic modulation of dopamine release in the three ascending pathways studied by in vivo microdialysis: comparison of naïve and chronic nicotine-treated rats. *J Neurochem* 1997;68:1511–9. [PubMed: 9084421]

- [117]. Rice ME, Cragg SJ. Nicotine amplifies reward-related dopamine signals in striatum. *Nature Neurosci* 2004;7:583–4. [PubMed: 15146188]
- [118]. Zhang H, Sulzer D. Frequency-dependent modulation of dopamine release by nicotine. *Nature Neurosci* 2004;7:581–2. [PubMed: 15146187]
- [119]. Marks MJ, Stitzel JA, Grady SR, Picciotto MR, Changeux JP, Collins AC. Nicotinic-agonist stimulated 86Rb+ efflux and [3H]spibatidine binding of mice differing in $\beta 2$ genotype. *Neuropharmacology* 2000;39:2632–45. [PubMed: 11044733]

***In Situ* Hybridization of nAChR Subunits (~ -3.0 mm Bregma)**

Figure 1.
in situ at level of SN/VTA. Frozen sections (14 μ m) from a C57Bl6 mouse at the level of SN/VTA (~-3.0mm bregma) were hybridized with full length riboprobes complementary to the $\alpha 2$, $\alpha 3$, $\alpha 4$, $\alpha 5$, $\alpha 6$, $\alpha 7$, $\beta 2$, $\beta 3$ and $\beta 4$ nAChR subunits [64,100].

Figure 2.

nAChR binding sites measurable with radiolabeled epibatidine. This diagram illustrates total mouse brain radiolabeled-epibatidine binding and the methods that can be used to subdivide this binding. Epibatidine binding in mouse brain is biphasic, with two sites differing significantly in affinity. Higher affinity refers to those receptor subtypes with K_D values of ~ 0.02 nM, while lower affinity receptors have K_D values of ~ 5 nM. Percentages throughout the diagram indicate the relative abundance of particular subsets in whole brain; however, note that relative abundance does vary among brain regions. “Required” subunits are determined by loss of binding in null mutant mice. Partial dependence of binding on a subunit is noted by “sometimes”, “significant” or “primarily”. Two of these subsets have been well-characterized by other methods. Namely, higher-affinity cytisine-sensitive binding is the subset that is also measured directly by [3 H]-nicotine or [3 H]-cytisine binding, while the lower-affinity α Bgt-sensitive subset is the nAChR measured directly by [125 I]- α -bungarotoxin binding. In addition, the α -CtxMII-sensitive subset can be measured directly by [125 I]- α -CtxMII binding ($K_i < 1$ nM). The α -CtxMII-resistant subset includes some receptors with moderate affinity for α -CtxMII ($K_i > 10$ nM).

Figure 3. nAChR binding in striatum. Specific binding to nAChRs was measured in striatal membrane preparations from mice of the three genotypes (wildtype, heterozygous, and null mutant) of each nAChR subunit null mutation indicated on the x-axis. Panel A: Binding representing the $\alpha 4\beta 2^*$ subtypes was measured by nicotine binding for the $\beta 3$ null genotypes [100], and by higher-affinity cytosine-sensitive [^3H]epibatidine binding for the remaining genotypes ($\alpha 5$ data from [86]; $\beta 2$ from [119]; $\alpha 4$, $\alpha 7$ and $\beta 4$ unpublished data from MJ Marks). Panel B: Binding representing the $\alpha 6\beta 2^*$ subtypes was measured by [^{125}I]- α -CtxMII binding (from [86]). For both panels, significant differences (1-way ANOVA) are indicated by * (different from wildtype $P < 0.05$) or + (different from heterozygote $P < 0.05$).

Figure 4.

Agonist-stimulated dopamine release from striatal synaptosomes. Panel A: $\alpha\text{-CtxMII}$ partially inhibits nicotine-stimulated dopamine release, evoked by a 10s exposure to 10 μM ACh, with an IC_{50} value of 2.2nM (data from [63]). Units indicate dopamine release as cpm normalized to cpm of baseline release. Panel B: ACh-stimulated dopamine release measured from C57Bl striatal synaptosomes with (MII resistant activity) and without (total activity) prior exposure to $\alpha\text{-CtxMII}$ (50nM for 5 min). The MII-sensitive activity is determined by difference (from [42]). Units are calculated as for Panel A. Panel C: $\alpha\text{-CtxMII}$ -resistant dopamine release stimulated by various agonists as % of maximal $\alpha\text{-CtxMII}$ -resistant release by ACh (replotted from [42]). Panel D: $\alpha\text{-CtxMII}$ -sensitive dopamine release stimulated by various agonists as

% of maximal α -CtxMII-sensitive release by ACh (replotted from [42]). Panel E: Inhibition of both α -CtxMII-resistant and —sensitive dopamine release stimulated by nicotine (3 μ M) by MLA (from [42]). Panel F: Inhibition of both α -CtxMII-resistant and —sensitive dopamine release stimulated by nicotine (3 μ M) by DH β E (from [42]).

Figure 5.

Effect of nAChR subunit null mutations on agonist-stimulated dopamine release from striatal synaptosomes. Panel A: Effects on α -CtxMII-resistant dopamine release by ACh (10 μ M) with prior exposure to α -CtxMII (50nM for 5 min) as % of wildtype response (replotted from [42] and unpublished data from SR Grady). Panel B: Effects on α -CtxMII-sensitive dopamine release stimulated by ACh (1 μ M) by difference between samples of synaptosomes with and without prior exposure to α -CtxMII (50nM for 5 min) as % of wildtype response (replotted from [42] and unpublished data from SR Grady). For both panels significant differences (1-way ANOVA) are indicated by * (different from wildtype $P < 0.05$) or + (different from heterozygote $P < 0.05$).